Collegium Pharmaceutical, Inc. (NASDAQ:COLL) management will conduct a conference call for 5th November 2020 at 4:30 PM Eastern Time to discuss financial results and companys performance for 3Q20.
The conference call will also be available live on the website www.collegiumpharma.com
Earnings Expectation
Collegium Pharmaceutical, Inc. is reporting third quarter financial results on Thursday 5th November 2020, after market close.
According to analysts surveyed by Thomson Reuters, COLL is expected to report 3Q20 income of $ 0.22 per share from revenue of $ 77.43 million.
For the full year, analysts anticipate top line of $ 309.77 million, while looking forward to income of $ 0.73 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 300.00 million ~ $ 320.00 million
Click Here For More Historical Outlooks Of Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, heating, and injecting. The company offers Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for opioid medication.
